Compare iShares China Large-Cap ETF (FXI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs TransMedics Group Inc — how do they compare? iShares China Large-Cap ETF trades at $35.18, while TransMedics Group Inc trades at $87.08 (market cap $3.10B). Which is the better fit depends on your goals.
| FXI | TMDX | |
|---|---|---|
52-Week High | $41.75 | $150.42 |
52-Week Low | $31.59 | $61.99 |
Market Cap | — | $3.10B |
Sector | — | Technology |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $35.23, down 3.45% on the day amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, while oscillators remain neutral. The ETF benefits from China's export strength and AI-driven manufacturing rebound, though financial ratios are currently unavailable. Recent news highlights China's 23% July export growth and ongoing infrastructure investments to support economic stability.
FXI offers exposure to China's large-cap recovery with state-backed stimulus and AI export growth as key catalysts. However, geopolitical tensions and US-China tech restrictions pose significant risks. The ETF's heavy financial sector weighting provides stability but limits pure tech exposure, requiring careful monitoring of China's economic policies and global trade dynamics.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
